0000000000726575

AUTHOR

Francesco Barillà

showing 6 related works from this author

Coronavirus disease 2019 infection and the cardiovascular system

2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralAntiviral AgentsCardiovascular SystemSettore MED/11Renin-Angiotensin SystemBetacoronavirusPandemicHumansMedicinePandemicsHost Microbial InteractionsbiologySARS-CoV-2business.industryCOVID-19General Medicinebiology.organism_classificationmedicine.diseaseVirologyCOVID-19 Drug TreatmentPneumoniaCardiovascular DiseasesCoronavirus InfectionsCardiology and Cardiovascular MedicinebusinessBetacoronavirusJournal of Cardiovascular Medicine
researchProduct

An expression of concern on research during the Covid-19 pandemic

2020

2019-20 coronavirus outbreakBiomedical ResearchCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralScientific MisconductSettore MED/11BetacoronavirusRetraction of Publication as TopicPandemicHumansMedicinePandemicsClinical Trials as TopicbiologySARS-CoV-2business.industryCOVID-19Reproducibility of ResultsGeneral Medicinebiology.organism_classificationVirologyCoronavirus InfectionsCardiology and Cardiovascular MedicinebusinessBetacoronavirusCoronavirus Infections
researchProduct

Pulmonary hypertension in pediatrics. a feasible approach to bridge the gap between real world and guidelines

2019

Pulmonary hypertension (PH) is quite infrequent in pediatric age and its most common etiologies include idiopathic pulmonary arterial hypertension, PH related to congenital heart diseases, bronchopulmonary dysplasia (chronic lung disease), persistence of pulmonary hypertension of the newborn, and congenital diaphragmatic hernia. The developed for adult patients PH classification shows limitations when applied to pediatric subjects since the underlying causes are markedly different between the two ages. In 2011, the Pulmonary Vascular Research Institute Panama Task Force outlined the first specific pediatric pulmonary hypertensive vascular disease diagnostic classification, including 10 main…

Right heart catheterizationAdultHeart Defects CongenitalPediatricsmedicine.medical_specialtynewbornsHypertension Pulmonary030204 cardiovascular system & hematologyBridge (interpersonal)Pediatrics03 medical and health sciences0302 clinical medicinechildrenpulmonary arterial hypertensionpulmonary hypertensionmedicineHumansright heart catheterizationChildBronchopulmonary Dysplasiabusiness.industrychildren; congenital heart disease; newborns; pulmonary arterial hypertension; pulmonary hypertension; right heart catheterizationIdiopathic Pulmonary Arterial HypertensionInfant NewbornObstetrics and GynecologyPediatric agemedicine.diseasePulmonary hypertensioncongenital heart disease030228 respiratory systemPediatrics Perinatology and Child HealthEtiologybusinessHernias Diaphragmatic Congenital
researchProduct

The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High

2020

Since its outbreak in China at the end of 2019, the new coronavirus disease (COVID-19) was characterized by both easy spreading and high mortality. The latter proved to be way more elevated in the North of Italy -with a peak of 18.4% in region Lombardia and even 31% in the city of Bergamo and surrounding county- than in the rest of the world. In an attempt to conceptualize the reasons for such a dramatic situation, four key elements have been identified: COVID-19 itself, old age, lung disease, and heart failure. Their harmful combination has been named “The deadly quartet”. The underlying risk factors, among which a lot of them are distinctive features of the population in northern Italy, …

Lung Diseases0301 basic medicineCoronavirus disease 2019 (COVID-19)PopulationcoronavirusheartDiseasemedicine.disease_causeArticleDisease OutbreakslungScientific evidenceSettore MED/1103 medical and health sciences0302 clinical medicineRisk FactorsHumansMedicineChinaeducationAgedCoronavirusHeart Failureeducation.field_of_studySARS-CoV-2business.industryAge FactorsCOVID-19OutbreakGeneral Medicinemedicine.diseasemortality030104 developmental biologyItaly030220 oncology & carcinogenesisHeart failureCardiology and Cardiovascular MedicinebusinessDemographyCurrent Cardiology Reviews
researchProduct

Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications.

2020

: ACE2 receptor has a broad expression pattern in the cellular membrane and provides a protective action against the development of cardiovascular diseases. Recently, this enzyme has become of extreme interest during the pandemic infection of COVID-19 (coronavirus disease 2019). This virus invades alveolar epithelium and cardiomyocytes using ACE2 as a transmembrane receptor. ACE2 is a counter-regulatory peptide that degrades Ang II into Ang 1-7, thereby attenuating the biological effects of the AT1 receptor. The binding between the spike protein of COVID-19 and the enzyme is crucial for the virus to enter the target cells, but whether an increase in ACE2 activity could facilitate the infect…

Angiotensin receptorARDSMyocarditisPneumonia ViralAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyPharmacologyPeptidyl-Dipeptidase AVirusSettore MED/11Renin-Angiotensin System03 medical and health sciencesAngiotensin Receptor AntagonistsBetacoronavirus0302 clinical medicinemedicineHumans030212 general & internal medicineReceptorPandemicsDisseminated intravascular coagulationAngiotensin II receptor type 1business.industrySARS-CoV-2COVID-19General MedicineVirus Internalizationmedicine.diseaseCardiovascular DiseasesAngiotensin-converting enzyme 2Spike Glycoprotein CoronavirusAngiotensin-Converting Enzyme 2Cardiology and Cardiovascular MedicinebusinessCoronavirus Infectionshormones hormone substitutes and hormone antagonistsJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

2020

Abstract Aims To evaluate the impact of the COVID-19 pandemic on patient admissions to Italian cardiac care units (CCUs). Methods and Results We conducted a multicentre, observational, nationwide survey to collect data on admissions for acute myocardial infarction (AMI) at Italian CCUs throughout a 1 week period during the COVID-19 outbreak, compared with the equivalent week in 2019. We observed a 48.4% reduction in admissions for AMI compared with the equivalent week in 2019 (P < 0.001). The reduction was significant for both ST-segment elevation myocardial infarction [STEMI; 26.5%, 95% confidence interval (CI) 21.7–32.3; P = 0.009] and non-STEMI (NSTEMI; 65.1%, 95% CI 60.3–70.3; P …

MaleMyocardial Infarction030204 cardiovascular system & hematologySettore MED/110302 clinical medicineAcute myocardial infarction Cardiac care units STEMI Aged Aged 80 and over COVID-19 Female Hospitalization Humans Italy Male Middle Aged SARS-CoV-2 Betacoronavirus Coronavirus Infections Myocardial Infarction Pandemics Pneumonia ViralCase fatality rate80 and overMedicine030212 general & internal medicineMyocardial infarctionViralAged 80 and overAcute myocardial infarction; Cardiac care units; COVID-19; SARS-CoV2; STEMI; Aged; Aged 80 and over; Female; Hospitalization; Humans; Italy; Male; Middle Aged; Betacoronavirus; Coronavirus Infections; Myocardial Infarction; Pandemics; Pneumonia ViralMiddle AgedHospitalizationItalyFemaleCardiology and Cardiovascular MedicineCoronavirus InfectionsHumanmedicine.medical_specialtyPneumonia ViralFast Track Clinical ResearchCardiac care unitsAcute myocardial infarctionSTEMI03 medical and health sciencesBetacoronavirusCardiac care unitHumansAcute myocardial infarction; COVID-19; Cardiac care units; SARS-CoV2; STEMIcardiovascular diseasesPandemicsAgedBetacoronaviruPandemicbusiness.industryCoronavirus InfectionSARS-CoV-2COVID-19Pneumoniamedicine.diseaseacute myocardial infarction; cardiac care units; COVID-19; SARS-CoV2; STEMIConfidence intervalRelative riskEmergency medicineSettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARESARS-CoV2Myocardial infarction complicationsObservational studyMyocardial infarction diagnosisbusinessComplication
researchProduct